Form 4: Frazier Life Sciences X, L.P. Reports Beneficial Ownership Changes in MBX Biosciences Following IPO

Frazier Life Sciences X, L.P. reports changes in beneficial ownership of MBX Biosciences stock following the company's initial public offering on September 16, 2024.

Summary

• Frazier Life Sciences X, L.P., along with related entities, filed a Form 4 detailing changes in beneficial ownership of MBX Biosciences, Inc. common stock.
• The filing reflects transactions related to the conversion of preferred stock into common stock and purchases made during the company's IPO on September 16, 2024.
• Frazier Life Sciences X, L.P. acquired 3,927,774 shares of common stock through the conversion of preferred stock.
• Additionally, Frazier Life Sciences X, L.P. purchased 625,000 shares at $16 per share in the IPO.
• Following these transactions, Frazier Life Sciences X, L.P. beneficially owns 4,552,774 shares of MBX Biosciences common stock.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to an IPO. It doesn't contain overtly positive or negative information, but the fact that a major investor participated in the IPO is generally a positive signal.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of MBX Biosciences following its IPO.
• Frazier Life Sciences X, L.P.'s participation in the IPO demonstrates continued investment in MBX Biosciences.
• The filing provides transparency regarding the ownership structure of MBX Biosciences.

Industry Context

Form 4 filings are standard practice following significant transactions such as IPOs, providing insight into the ownership structure of newly public companies. This filing indicates the holdings of a major investor, Frazier Life Sciences, post-IPO.

Stakeholder Impact

• Shareholders gain insight into the ownership structure of the company post-IPO.
• The filing provides transparency to the market regarding significant transactions by major shareholders.

Key Dates